In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How To Withdraw A Drug: FDA’s Final Decision on Avastin

Executive Summary

The “streamlined withdrawal” process for Avastin in metastatic breast cancer gave Genentech an extra 11 months to prepare for the transition to off-label status. It also gave FDA time to make preparations of its own.

Advertisement

Related Content

MS Boon: Many Drugs On The Way, But Will Payors Swallow The Cost?
Lack Of MS Clinical Guidelines Presents Challenge To Payers
Avastin Loses Its Breast Cancer Claim; FDA’s Hamburg Opts For Withdrawal Over Restrictions
Roche and FDA in Oncology: Fighting in Public, Collaboarting in Private
Never Again? Why the Avastin Hearing May Be One of a Kind
Avastin and FDA/CMS Coordination: Genentech's Safe Strategy to Save Medicare Coverage

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003733

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel